Amarin : Q1 2025 Earnings Presentation

Published: 2025-05-07 09:41:21 ET AMRN

Published on 05/07/2025 at 09:41

May 7, 2025

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, guidance, and other statements.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks

of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

Aaron Berg, President & CEO

Peter Fishman, SVP, Chief Financial Officer

Aaron Berg, President & CEO

04 Q&A

FIRST QUARTER 2025 STATE OF THE BUSINESS: AN UPDATE

Aaron Berg

President & CEO

Europe:

Realized sequential growth in In-market demand across all markets where VAZKEPA launched, driven primarily by Spain, UK & CEE

Continued progress in building market access in Italy

Secured pricing & reimbursement in Austria; continued traction with pricing & reimbursement authorities in other EU markets (Norway, Ireland)

U.S.:

Maintained significant absolute contribution of highly profitable cash generation from VASCEPA, despite additional generic competition (price & volume impact)

Ready to launch authorized generic when optimal

RoW:

China: Edding continued CVRR launch in private pay market; working towards National Reimbursement Drug List (NRDL) review for 2026

Australia: CSL efforts led to VAZKEPA included in National Heart Foundation/Cardiac Society Acute Coronary Syndrome guidelines

Saudi Arabia: Biologix made progress with the Ministry of Health for VAZKEPA inclusion on public health formulary

Other: Continued to advance regulatory progress in seven additional markets, primarily in Southeast Asia

Completed 1-for-20 ADS Ratio Change

Regained compliance with Nasdaq minimum bid price requirement, resulting in the Company's continued listing on Nasdaq under ticker symbol AMRN

Generated $42.0 million in total revenues, including $5.4 million contribution from Europe markets

Realized operating expenses of $41.9 million, a reduction of 8% versus prior year, reflecting impact of ongoing cost optimization initiatives

Maintained significant cash position, with $281.8 million and no debt, reinforcing the benefits of continued prudent cash management and a strong capital structure

BUSINESS UPDATE

Q1 2025: PROGRESS UPDATE

Disclaimer

Amarin Corporation plc published this content on May 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2025 at 13:40 UTC.